VAŽNOST PROCENE HEMORAGIJSKOG RIZIKA ZA PRIMENU ANTITROMBOTSKE TERAPIJE U AKUTNOM KORONARNOM SINDROMU

Miodrag M Cekić

doi:10.5937/racter5-2351

Miodrag M Cekić "Bayer d.o.o. Beograd, Bayer HealthCare Pharmaceuticals"

DOI: https://doi.org/10.5937/racter5-2351

Ključne reči: risk evaluation||, ||Procena rizika, bleeding||, ||Krvarenje, antithrombotic therapy||, ||Antitrombotska terapija, acute coronary syndrome||, ||Akutni koronarni sindrom,

Sažetak

Antitrombotska terapija u akutnom koronarnom sindromu, usmerena na sprečavanje i minimiziranje ishemijskih komplikacija, je efikasna i opravdana, ali moguće krvarenje kao njena komplikacija ostavlja otvoreno pitanje gde je granica između njene efikasnosti i bezbednosti. Krvarenje povećava mortalitet i do sedam puta u prvih mesec dana od započinjanja antitrombotske terapije. Stepen hemoragijskog rizika zavisi od brojnih faktora: pola, godina starosti, pridruženih bolesti, kliničke slike u akutnom koronarnom sindromu, klirensa kreatinina, kao i od terapijskog pristupa i lokalizacije krvarenja. Cilj ovog rada je da se ukaže na značaj procene hemoragijskog rizika za adekvatan izbor i doziranje antitrombotskih lekova, kako bi se uspostavila ravnoteža između njihove efikasnosti i bezbednosti i poboljšala prognoza bolesti. Do danas je razvijeno nekoliko skoring sistema za procenu rizika od krvarenja, a njihova primena se preporučuje u svakodnevnom radu.

Biografija autora

Miodrag M Cekić, "Bayer d.o.o. Beograd, Bayer HealthCare Pharmaceuticals"

Doktor medicine, specijalizant kliničke farmakologije

Reference

Cannon CP, Braunwald E. Unstable Angina and Non-ST Elevation Myocardial Infarction. In Braunwald, Zipes, Libby (Eds): Heart Disease, Textbook of Car-diovascular Medicine 8th ed. W. B. Saunders Com-pany, 2008 Philadelphia, pp. 1319-51

Bassand J, Hamm CW, Ardissino D et al. Guidelines for the diagnosis and treatment of non-ST-segment ele-vation acute coronary syndromes. Eur Heart J 2007; 28(13): 1598-660.

Mackay J, Mensah GA, Mendis S, Greenlund K. The Atlas of Heart Disease and Stroke. Geneva: World Health Organization. 2004.

Incidencija i mortalitet od akutnog koronarnog sindro-ma u 2006, 2007, 2008, 2009. Beograd: Institut za jav-no zdravlje republike Srbije 'Dr Milan Jovanović Batut. [cited 2012 Jul 8]. Preuzeto sa: www.batut.org.rs

Andrade PB, Tebet MA, Maia SFS, Athanazio AMV, Labrunie A, Piva MLAE. Major bleeding in acute coronary syndromes. J Invasive Cardiol 2011; 23(11): 485-90.

Arman TA, Lincoff AM. Antithrombotic Drug The-rapy in Cardiovascular Disease. Humana Press, a part of Springer Science+Business Media, LLC, 2010.

Steen Husted. Benefits and risks with antiplatelet the-rapy: how great a problem is bleeding? European Heart Journal Supplements. 2008; 10 (Supplement I), I19–I24.

Tunstall-Pedoe H. How cardiovascular risk varies with age sex, and coronary risk factors: Do standard risk scores give an accurete perspective. Eur Heart J Suplements 1999;1(suppl D): D25-D31.

Rao SV, Eikelboom JA, Granger CB, Harrington RA, Califf RM, Bassand J. Bleeding and blood transfusion issues in patients with non-ST-segment elevation acute coronary syndromes. Eur Heart J 2007; 28(10): 1193-204.

Eikelboom JW, Mehta SR, Anand SS, Xie C, Fox KAA, Yusuf S. Adverse impact of bleeding on prog-nosis in patients with acute coronary syndromes. Cir-culation 2006; 114(8): 774-82.

Lopes RD, Alexander KP, Manoukian SV et al. Advanced age, antithrombotic strategy, and bleeding in non-ST-segment elevation acute coronary syndromes: results from the ACUITY (Acute Catheterization and Urgent Intervention Triage Strategy) trial. J Am Coll Cardiol 2009; 53(12): 1021-30.

Kažić T, Ostojić M. (urednici) Klinička kardiovasku-larna farmakologija. 5. izdanje, Integra, Beograd, 2009.

Manoukian SV. Predictors and impact of bleeding complications in percutaneous coronary intervention, acute coronary syndromes, and ST-segment elevation myocardial infarction. Am J Cardiol 2009; 104: 9-15.

Verheugt FWA, Steinhubl SR, Hamon M, et al. Incidence, prognostic impact, and influence of antithrombotic therapy on access and nonaccess site bleeding in percutaneous coronary intervention. J Am Coll Cardiol 2011; 4: 191-7.

Nikolsky E, Stone GW, Kirtane AJ, et al. . Gastrointestinal bleeding in patients with acute coronary syndromes: Incidence, predictors, and clinical implications. J Am Coll Cardiol 2009; 54: 1293-302.

Gaglia MA, Torguson R, Gonzalez MA, et al. Cor-relates and consequences of gastrointestinal bleeding complicating percutaneous coronary intervention.. Am J Cardiol 2010; 106: 1069-74.

Graham I, Atar D, Borch-Johansen K et al. European guidelines on cardiovascular disease prevention in clinical practice. Eur J Cardiovas Prev Rehabil 2007; 14(suppl 2): 1-113.

Sanchis J, Bodí V, Núñez J et al. New risk score for patients with acute chest pain, non-ST-segment deviation, and normal troponin concentrations: A com-parison with the TIMI risk score. J Am Coll Cardiol 2005; 46(3): 443-9.

Gonçalves PA, Ferreira J, Carlos ACA. TIMI, PUR-SUIT, and GRACE risk scores: Sustained prognostic value and interaction with revascularization in NSTE-ACS. Eur Heart J 2005; 26(9): 865-72.

Moscucci M, Fox KAA, Cannon CP et al. Predictors of major bleeding in acute coronary syndromes: the Global Registry of Acute Coronary Events (GRACE). Eur Heart J 2003; 24(20): 1815-23.

Nikolsky E, Mehran R, Dangas GD et al. Development and validation of a prognostic risk score for major bleeding in patients undergoing percutaneous coronary intervention via the femoral approach. Eur Heart J 2007; 28(16): 1936-45.

Mehran R, Pocock SJ, Nikolsky E et al. A risk score to predict bleeding in patients with acute coronary syn-dromes. J Am Coll Cardiol 2010; 55(23): 2556-66.

Subherwal S, Bach RG, Chen AY, et al. Baseline risk of major bleeding in non-ST-segment-elevation myocardial infarction: The CRUSADE (Can Rapid risk stratification of Unstable angina patients Suppress ADverse outcomes with Early implementation of the ACC/AHA guidelines. Circulation 2009; 119: 1873-82.

CRUSADE Bleeding Score. www.crusadebleedingscore.org (accessed on 08 September 2012).